[Changes in lipid metabolism of patients infected by human immunodeficiency virus. A pathogenic hypothesis].
Rodríguez Vidigal
F F
FF
Departamento de Medicina Interna, Hospital Universitario Infanta Cristina, Insalud-Universidad de Extremadura, Badajoz.
Muñoz Sanz
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000378:metabolism; D019380:Anti-HIV Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology; D005223:Fats / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D019247:HIV Wasting Syndrome / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000378:metabolism; D006951:Hyperlipoproteinemias / Q000209:etiology / Q000378:metabolism; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008060:Lipodystrophy / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics / Q000628:therapy; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D012307:Risk Factors
D019380:Anti-HIV Agents; D005223:Fats; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors